https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51348 Wed 28 Feb 2024 15:50:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45250 Wed 26 Oct 2022 15:22:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:2011 Wed 24 Jul 2013 22:53:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47089 Wed 14 Dec 2022 09:30:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13534 Wed 11 Apr 2018 14:07:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:6940 Wed 11 Apr 2018 09:50:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51633 Wed 01 May 2024 11:50:26 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48312 P < 0.001] between 2013 and 2016. NSWPIC received 1158 reports of intentional pregabalin poisonings, with a 53.8% increase per year, 2005–2016 (95% CI = 44.0–64.2%, P < 0.001). We identified 88 pregabalin‐associated deaths, 57.8% yearly increase (95% CI = 30.0–91.6%, P < 0.001). Patients overdosing on pregabalin commonly co‐ingested opioids, benzodiazepines and illicit drugs, and had high rates of psychiatric and substance use comorbidities; 14.7% of pregabalin users were classed by the LCA as at high risk of misuse, and were more likely to be younger, male, co‐prescribed benzodiazepines or opioids, have more individual prescribers and higher pregabalin strengths dispensed. Conclusions: There has been a dramatic increase in pregabalin use, poisonings and deaths in Australia since it became subsidized publicly in 2013. One in seven Australians dispensed pregabalin appears to be at high risk of misuse.]]> Tue 14 Mar 2023 14:48:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54299 Thu 15 Feb 2024 14:53:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11391 Sat 24 Mar 2018 10:32:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7616 Sat 24 Mar 2018 08:34:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10039 Sat 24 Mar 2018 08:12:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18164 90% of general practices computerized. Recent eHealth incentives promote the use of up to date electronic information sources relevant to general practice with flexibility in mode of access. Objective: To determine GPs’ access to and use of electronic information sources and computerized clinical decision support systems (CDSSs) for prescribing. Methods: Semi-structured interviews were conducted with 18 experienced GPs and nine GP trainees in New South Wales, Australia in 2008. A thematic analysis of interview transcripts was undertaken. Results: Information needs varied with clinical experience, and people resources (specialists, GP peers and supervisors for trainees) were often preferred over written formats. Experienced GPs used a small number of electronic resources and accessed them infrequently. Familiarity from training and early clinical practice and easy access were dominant influences on resource use. Practice time constraints meant relevant information needed to be readily accessible during consultations, requiring integration or direct access from prescribing software. Quality of electronic resource content was assumed and cost a barrier for some GPs. Conclusions: The current Australian practice incentives do not prescribe which information resources GPs should use. Without integration into practice computing systems, uptake and routine use seem unlikely. CDSS developments must recognize the time pressures of practice, preference for integration and cost concerns. Minimum standards are required to ensure that high-quality information resources are integrated and regularly updated. Without standards, the anticipated benefits of computerization on patient safety and health outcomes will be uncertain.]]> Sat 24 Mar 2018 08:04:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16965 Sat 24 Mar 2018 07:55:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27972 Sat 24 Mar 2018 07:38:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52532 Mon 16 Oct 2023 16:35:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46587 Misuse is not the main problem) contextualised misuse as a relatively minor concern compared with pain control and toxicity, and highlighted underlying systemic factors, including limitations in continuity of care and doctor expertise. Theme 2 (‘A different mindset’ for cancer pain) captured participants’ relative comfort in prescribing opioids for pain in cancer versus non-cancer contexts, and acknowledgement that compassion and greater perceived community acceptance were driving factors, in addition to scientific support for mechanisms and clinical efficacy. Participant attitudes towards prescribing for people with cancer versus non-cancer pain differed most when cancer was in the palliative phase, when they were unconcerned by misuse. Participants were equivocal about the risk–benefit ratio of long-term opioid therapy in the chronic phase of cancer, and were reluctant to prescribe for disease-free survivors. Theme 3 (‘The question is always, ‘how lazy have you been?’) captured participants’ acknowledgement that they sometimes prescribed opioids for cancer pain as a default, easier option compared with more holistic pain management. Conclusions: Findings highlight the role of specific clinical considerations in distinguishing risk of opioid misuse in the cancer versus non-cancer population, rather than diagnosis per se. Further efforts are needed to ensure continuity of care where opioid prescribing is shared. Greater evidence is needed to guide opioid prescribing in disease-free survivors and the chronic phase of cancer, especially in the context of new treatments for metastatic disease.]]> Fri 25 Nov 2022 14:52:26 AEDT ]]>